NCT05901194View on ClinicalTrials.gov

Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
DRUG

Lenvatinib

Lenvatinib will be administred orally and daily at the usual dose ( 8 or 12 mg per day depending on the weight \< or ≥ 60kg) in the 25 patients of the study from TACE failure until LT

Trial Locations (6)

Unknown

Hospital Haut levêque, Bordeaux

Hospital Henri Mondor, Créteil

Hospital Claude Huriez, Lille

Pontchaillou Hospital, Rennes

Hospital Trousseau, Tours

Paul Brousse Hospital, Villejuif

Sponsors

Collaborators (1)

Laboratoire EISAI
All Listed Sponsors
collaborator

Laboratoire EISAI

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT05901194 - Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter